infectious-diseases-2016_keynote

8 / 17

Volume 4, Issue 4(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Infectious Diseases 2016
August 24-26, 2016
Page 51
Notes:
conferenceseries.com
August 24-26, 2016 Philadelphia, USA
&
Infectious DiseasesJoint Event on 2nd World Congress on
Pediatric Care & Pediatric Infectious Diseases
International Conference on
Glenn S Tillotson, J Infect Dis Ther 2016, 4:4(Suppl)
Globalization of the unmet need of new antibiotics
Bacterial resistance to antibiotics is an escalating problem. There are significant efforts expanded in the battle to combat
this problem. Recent infectious diseases have hit the media especially viral infections such as Ebola, Zika and currently
Yellow Fever. The dissemination of these infections is especially worrying but we seem to have played down the bacterial
diseases. However, with increasing travel and the growing crisis of refugees it is obvious that the transfer of resistant bacterial
infections is highly likely or under-appreciated. Recent examples include azithromycin resistant Shigella sonnei infections;
NDM-1 Klebsiella pneumoniae and other pathogens were from overseas. Additionally resistant infections may transfer within
a country where there may be marked susceptibility differences. So what may be the implications of this situation? Companies
both small and large are developing antibiotics to combat this issue are faced with multiple regulatory processes. These can
be challenging both in terms of completion and in terms of costs. As these issues become more global, there needs to be a
mechanism by which a streamlined development process applied so each country or region does not need to repeat or require
their own unique evaluations to approve a new antibiotic. The clock is ticking and we are running out of options and as we
travel more this can only get worse.
Biography
Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications
including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and
launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of
solithromycin for community acquired bacterial pneumonia. He has published more than 170 peer-reviewed manuscripts and is on several journal Editorial Advisory
Boards including the Lancet Infectious Disease, eBioMedicine, Expert Reviews in Anti-infective Therapy and F1000.
Glenn S Tillotson
Cempra Pharmaceuticals, USA